Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency
Authors' conclusion
The Covid-19 vaccines appear well-tolerated in patients with AI, with similar frequency of symptoms to that reported in the background population. The AZ vaccine leads to slightly greater post-vaccination symptom burden and need to increase glucocorticoid dosage, but this does not translate to greater adverse outcomes.
Study context
- Population
- Patients with adrenal insufficiency (AI) of any aetiology who received the Covid-19 vaccine279 completed
- Participants
- 290 patients
- Exposure
- mRNA vs adenovirus vector Covid-19 vaccines
- Astra Zeneca (AZ)n = 176
- Pfizer-BioNTech (PB)n = 100
- MDn = 3
- Outcome
- Moderate to severe symptoms after vaccination
Methodological detailsstructured questionnaire
- Structured questionnaire
Main finding
As reported in the abstract
- Moderate to severe symptoms after first vaccine
- 44.8%
- Moderate to severe symptoms after second vaccine
- 39.7%
- Onset after first vaccine, h (IQR)
- 6.0 (2-12)
- Onset after second vaccine, h (IQR)
- 6.0 (2-24)
- Duration after first vaccine, h (IQR)
- 24 (12-72)
- Duration after second vaccine, h (IQR)
- 26 (12-72)
Observational data: associations, not effects.
Further findings
Increased maintenance glucocorticoid dose · after first and second vaccines
- After first vaccine
- 34.4%
- After second vaccine
- 29.7%
Original publication
Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency. Pituitary. Published 17 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →